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Foxp3+ Treg cells express transcription factors normally expressed by specific T helper cells at sites of
inflammation. In this issue of Immunity, Koch et al. (2012) and Hall et al. (2012) demonstrate that IFN-g and
IL-27 distinctly induces T-bet+ Treg cells via STAT-1 transcription factor activation.CD4+ T cells are important for host
defense in their role as specialized T
helper (Th) cell subsets (e.g., Th1, Th2,
Th17, and Tfh), which express specific
transcription factors, such as T-bet,
Gata3, IRF4, RORgt, and BCL-6. Foxp3+
regulatory T (Treg) cells, in contrast, are
indispensable for the maintenance of
immune tolerance and homeostasis via
mainly controlling the development and
expansion of these Th cell populations
(Sakaguchi et al., 2008). Recent studies
have shown that Foxp3+ Treg cells are
able to sense cytokine signals in the
environment and further differentiate to
control specific type of inflammation via
expressing transcription factors specifi-
cally associated with the differentiation
and function of Th cell subsets. In this
issue of Immunity, Koch et al. (2012) and
Hall et al. (2012) demonstrate that T-bet+
Treg cells, one of such specialized Treg
cell subpopulations, are induced in
a STAT1-dependent manner by exposure
to the cytokine IFN-g or IL-27 and that
each cytokine has distinct roles in driving
T-bet+ Treg cells at inflammation sites.
The transcription factor T-bet, normally
required for Th1 cell development, is
upregulated in Treg cells in response to
IFN-g, and T-bet-deficient Treg cells fail
to rescue Foxp3-deficient mice from
Th1 cell-mediated inflammatory disease
(Koch et al., 2009). T-bet induces the
Th1 cell-associated chemokine receptorCXCR3, which enables the T-bet+ Treg
cells to migrate to a type 1 inflammation
site and suppress local Th1 cell immune
responses. Similarly IRF4+ Treg cells
control type 2 inflammation: Treg-specific
deletion of Irf4, which is critical for Th2
cell differentiation, results in the failure
of these Treg cells to efficiently sup-
press Th2 cell-mediated immunopa-
thology (Zheng et al., 2009). In addition,
Treg cell-specific deficiency of the tran-
scription factor STAT3, which is essential
for proper development of Th17 cells, fails
to suppress Th17 cell-mediated disease,
indicating the role of STAT3+ Treg cells
in controlling Th17 cell immune responses
(Chaudhry et al., 2009). Thus, the ability of
Foxp3+ Treg cells to control different
types of Th cell responses crucially
depends on their expression of specific
Th cell-associated transcription factors.
Key issues are then how they acquire
such inflammation type-specific suppres-
sive activities and how the activities are
maintained during inflammation.
In this issue, Koch et al. (2012) have
investigated the molecular pathway lead-
ing to the upregulation of T-bet in Foxp3+
Treg cells and explored possible mecha-
nisms by which T-bet+ Treg cell function
ismaintained in Th1 cell-polarizing inflam-
matory environments. They showed that
activation of STAT1 by IFN-g derived
from activated Th1 cells induced T-bet
expression in Treg cells. Notably, despitesimilar induction of CXCR3 expression in
both Foxp3+ and Foxp3 T cells via
T-bet activation, the levels of IL-12 re-
ceptor expression were different between
the two populations. The expression of
the receptor component IL-12Rb2, which
is induced in naive T cells after STAT1 and
T-bet activation, was refractory to T-bet
expression in Foxp3+ Treg cells in part
because of altered epigenetic status of
Il12rb2 locus in Treg cells. This prevented
T-bet+ Treg cells from completing IL-12-
STAT4-dependent Th1 cell differentiation
and thereby ensured their maintenance
of stable suppressive function without
producing pro-inflammatory Th1 cyto-
kines (Figure 1).
Hall et al. (2012) showed that not only
IFN-g but also IL-27 was able to activate
STAT1 in Treg cells, promote their expres-
sion of T-bet and CXCR3, and expand
such T-bet+CXCR3+ Treg cells. Previous
studies showed that IL-27, an inhibitory
cytokine in the setting of autoimmunity
and inflammation, did not alter Treg cell
suppressive activity and that the fre-
quency of Treg cells was not significantly
changed in IL-27Ra-defiecient mice
(Villarino et al., 2003). Interestingly, Hall
et al. (2012) showed that IL-27 deficiency
resulted in significant reduction of
T-bet+CXCR3+ Treg cells in the gut-asso-
ciated lymphoid tissues (GALTs), but not
in the spleen, during oral Toxoplasma
gondii infection, which induced Th1ptember 21, 2012 ª2012 Elsevier Inc. 443
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Figure 1. Generation of T-bet+ Treg cells by IFN-g or IL-27
T-bet+ Treg cells are induced by exposure to IFN-g in the periphery or IL-27 in the mucosal sites of inflam-
mation, such as gut-associated lymphoid tissues during T. gondii infection. In conventional T (Tconv) cells,
IFN-g activates STAT1, which upregulates the expression of T-bet, CXCR3, and the IL-12 receptor
component IL-12Rb2. IL-12 signaling via IL-12 receptor activates STAT4, which in turn upregulates Th1
cell-associated molecules, and completes Th1 cell differentiation. In contrast, in Treg cells, STAT1 acti-
vated by IFN-g upregulates T-bet and CXCR3, but not IL-12Rb2, leading to the deficiency of functional
IL-12 receptor. The lack of IL-12 signaling results in the abortion of Th1 cell developmental program in
Treg cells, establishing T-bet+ Treg cells without proinflammatory effector functions.
Immunity
Previewscell-dominant immune responses. In con-
trast, neutralization of IFN-g reduced the
expression of T-bet and CXCR3 in splenic
Treg cells but not in Treg cells in the GALT
of infected mice. Moreover, Treg cells
exposed to IL-27 had distinct tran-
scriptional profiles compared with those
exposed to IFN-g. These data collectively
highlighted distinct roles of IFN-g and
IL-27 for induction of T-bet+ Treg cells
and a dominant contribution of IL-27 at
the sites of ongoing Th1 cell inflammation.
These new findings of cytokine-
induced Treg cell differentiation in the
periphery have important implications
regarding how Treg cells control specific
types of inflammation. The results by
Koch et al. (2012) and Hall et al. (2012)
indicate that the guidance of Treg cells
to type 1 inflammation sites via IFN-g- or
IL-27-dependent expression of CXCR3
is critical for specifically controlling Th1
cell immune responses even if every
Treg cell has a common key mechanism
of suppression, for example, CTLA-
4-dependent modification of antigen-
presenting cell function. It remains to be444 Immunity 37, September 21, 2012 ª2012determined whether similar mechanisms
are also operative in other inflammation
type-specific Treg cells, for example,
whether Treg cells expressing IRF4 con-
trol type 2 inflammation via IRF4-
dependent expression of CCR8.
In addition to the effects on Treg cell
migration to inflammation sites, cytokines
may control Treg cell suppressive func-
tion. For example, IL-27 induced IL-10
production in T cells and Treg cells.
T-bet+ Treg cells, whether they were
induced by IFN-g or IL-27, abundantly
produced IL-10, which was required for
their suppression of type 1 inflammation
in T. gondii infection. IL-10 is also
produced by chronically stimulated Th1
cells in T. gondii infection (Jankovic
et al., 2007). It is thus likely that a cytokine
not only controls cell migration of both Th
and Treg cells but also confers suppres-
sive or anti-inflammatory function on
each population, thus dampening inflam-
mation in Th cell-intrinsic and -extrinsic
manners.
It is controversial whether Foxp3+ Treg
cells at a particular inflammation siteElsevier Inc.bear a plasticity to differentiate into non-
Treg cells, especially into proinflamma-
tory Th cells, via losing Foxp3 expression.
The conversion could be harmful because
Foxp3 Treg cells are supposed to bemore
self-reactive in antigen specificity. Koch
et al. (2012) showed that repression of
IL-12Rb2 expression in Treg cells pre-
vented their conversion to Th1 effector
T cells. Foxp3 binding sites were not
found in the adjacent regions of the
Il12rb2 locus (Zheng et al., 2007), and
that deletion of Foxp3 in Treg cells failed
to upregulate IL12Rb2 expression, indi-
cating that the repression of IL-12Rb2
expression is a Foxp3-independent pro-
gramof Treg cell differentiation. This cyto-
kine-dependent and Foxp3-independent
maintenance of functional or cell lineage
stability of Treg cells can be exploited to
generate and maintain functionally stable
Treg cells for clinical use.
Further investigation of how cytokines
and Th cell-specific transcription factors
regulate the function and differentiation
of Foxp3+ Treg cells is necessary for
better control of a variety of inflammation.
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